Urinary Tract Infections is an indication for drug development with over 110 pipeline drugs currently active. According to GlobalData, preregistered drugs for Urinary Tract Infections have a 84.62% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Urinary Tract Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Urinary Tract Infections overview
A urinary tract infection (UTI) is a bacterial infection that can occur in any part of the urinary system, including the kidneys, bladder, ureters, and urethra. Common symptoms include pain or burning during urination, frequent urination, urgency, lower abdominal discomfort, and cloudy or foul-smelling urine. UTIs are more common in women, and risk factors include factors such as sexual activity, urinary tract abnormalities, and weakened immune systems. Diagnosis is typically based on symptoms and a urine sample analysis. Treatment involves antibiotics, and preventive measures include staying hydrated, practicing good hygiene, and urinating before and after sexual activity. Prompt medical attention is important to prevent complications, such as kidney infections.
For a complete picture of PTSR and LoA scores for drugs in Urinary Tract Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
